Download PDF
Semin Thromb Hemost 2007; 33(7): 673-679
DOI: 10.1055/s-2007-991969
© Thieme Medical Publishers

The Role of Thrombomodulin in Malignancy

Ann M. Hanly1 , Desmond C. Winter1
  • 1Institute for Clinical Outcomes Research and Education (iCORE), St. Vincents University Hospital, Dublin, Ireland
Further Information

Publication History

Publication Date:
14 November 2007 (online)

    Permissions and Reprints

ABSTRACT

More than 150 years ago, Trousseau first suggested a link between cancer and thrombosis. Although this link has been widely described subsequently, the underlying mechanism still remains unclear. Thrombomodulin (TM), a natural endothelial anticoagulant, has proved itself to be an exciting molecule of many functions, not least of those in inflammation, thrombosis, and carcinogenesis. It has been highlighted and supported in many studies as having a cytoprotective role in many types of carcinoma; however, the mechanism of this role remains undefined. It is clear that TM exerts an influence on the endothelium and on the metastatic capacity of cancer, with elevated TM expression conferring a positive predictive and prognostic factor. Exactly how TM features in the metastatic pathway is unclear; however, once this has been clearly outlined, the opportunities afforded by inducers of TM expression may provide potential therapies to improve tumor behavior and impede transendothelial spread of cancer.

KEYWORDS

Thrombomodulin - inflammation - thrombosis - malignancy

REFERENCES

  • 1 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?.  Lancet. 2001;  357 539-545
    CrossrefPubMedGoogle Scholar
  • 2 Esmon C T, Fukudome K, Mather T et al.. Inflammation, sepsis, and coagulation.  Haematologica. 1999;  84 254-259
    PubMedGoogle Scholar
  • 3 Esmon C T, Gu J M, Xu J, Qu D, Stearns-Kurosawa D J, Kurosawa S. Regulation and functions of the protein C anticoagulant pathway.  Haematologica. 1999;  84 363-368
    PubMedGoogle Scholar
  • 4 Conway E M, Van de Wouwer M, Pollefeyt S et al.. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways.  J Exp Med. 2002;  196 565-577
    CrossrefPubMedGoogle Scholar
  • 5 Donati M B, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy.  Acta Haematol. 2001;  106 18-24
    CrossrefPubMedGoogle Scholar
  • 6 Falanga A, Donati M B. Pathogenesis of thrombosis in patients with malignancy.  Int J Hematol. 2001;  73 137-144
    CrossrefPubMedGoogle Scholar
  • 7 Rickles F R, Edwards R L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited.  Blood. 1983;  62 14-31
    PubMedGoogle Scholar
  • 8 Donati M B. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice.  Thromb Haemost. 1995;  74 278-281
    PubMedGoogle Scholar
  • 9 Donati M B, Poggi A. Malignancy and hemostasis.  Br J Haematol. 1980;  44 173-182
    PubMedGoogle Scholar
  • 10 Esmon C T. The roles of protein C and thrombomodulin in the regulation of blood coagulation.  J Biol Chem. 1989;  264 4743-4746
    PubMedGoogle Scholar
  • 11 Imada S, Yamaguchi H, Nagumo M, Katayanagi S, Iwasaki H, Imada M. Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays.  Dev Biol. 1990;  140 113-122
    CrossrefPubMedGoogle Scholar
  • 12 Hosaka Y, Higuchi T, Tsumagari M, Ishii H. Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin.  Cancer Lett. 2000;  161 231-240
    CrossrefPubMedGoogle Scholar
  • 13 de Munk G A, Groeneveld E, Rijken D C. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin.  J Clin Invest. 1991;  88 1680-1684
    PubMedGoogle Scholar
  • 14 Kokame K, Zheng X, Sadler J E. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C.  J Biol Chem. 1998;  273 12135-12139
    CrossrefPubMedGoogle Scholar
  • 15 Imada M, Imada S, Iwasaki H, Kume A, Yamaguchi H, Moore E E. Fetomodulin: marker surface protein of fetal development which is modulatable by cyclic AMP.  Dev Biol. 1987;  122 483-491
    CrossrefPubMedGoogle Scholar
  • 16 Dorffler-Melly J, de Kruif M, Schwarte L A et al.. Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis.  Basic Res Cardiol. 2003;  98 347-352
    CrossrefPubMedGoogle Scholar
  • 17 Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies.  Lupus. 1996;  5 388-392
    PubMedGoogle Scholar
  • 18 Altomonte L, Zoli A, Accili D, Mangia A, Bianco A, Magaro M. Thrombosis, recurrent abortions and intrauterine foetal death in a patient with lupus anticoagulant.  Clin Rheumatol. 1985;  4 455-457
    CrossrefPubMedGoogle Scholar
  • 19 Kaare M, Ulander V M, Painter J N, Ahvenainen T, Kaaja R, Aittomaki K. Variations in the thrombomodulin and endothelial protein C receptor genes in couples with recurrent miscarriage.  Hum Reprod. 2007;  22 864-868
    PubMedGoogle Scholar
  • 20 Nan B, Lin P, Lumsden A B, Yao Q, Chen C. Effects of TNF-alpha and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells.  Thromb Res. 2005;  115 417-426
    CrossrefPubMedGoogle Scholar
  • 21 Speiser W, Kapiotis S, Kopp C W et al.. Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies.  Thromb Haemost. 2001;  85 362-367
    PubMedGoogle Scholar
  • 22 Falanga A, Ofosu F A, Cortelazzo S et al.. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery.  Br J Haematol. 1993;  85 745-750
    PubMedGoogle Scholar
  • 23 Falanga A, Barbui T, Rickles F R, Levine M N. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Hemostasis and Malignancy International Society of Thrombosis and Hemostasis.  Thromb Haemost. 1993;  70 540-542
    PubMedGoogle Scholar
  • 24 Falanga A, Ofosu F A, Delaini F et al.. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions.  Blood Coagul Fibrinolysis. 1994;  5(Suppl 1) S19-S23 discussion 59-64
    PubMedGoogle Scholar
  • 25 O'Meara R A. The growth-pattern of carcinomas.  Arch De Vecchi Anat Patol. 1960;  31 365-384
    PubMedGoogle Scholar
  • 26 O'Meara R A. Coagulative properties of cancers.  Ir J Med Sci. 1958;  394 474-479
    PubMedGoogle Scholar
  • 27 O'Meara R A, Thornes R D. Some properties of the cancer coagulative factor.  Ir J Med Sci. 1961;  423 106-112
    PubMedGoogle Scholar
  • 28 Thornes R D, Martin W T. The cytopathic effect of fibrinolytic agents and human placental fractions on HeLa cells.  Ir J Med Sci. 1961;  431 487-494
    PubMedGoogle Scholar
  • 29 Thornes R D, O'Meara R A. A method of detecting and estimating inhibitors of the cancer coagulative factor.  Ir J Med Sci. 1961;  428 361-365
    PubMedGoogle Scholar
  • 30 Thornes R D, Daly L, Lynch G et al.. Treatment with coumarin to prevent or delay recurrence of malignant melanoma.  J Cancer Res Clin Oncol. 1994;  120(Suppl) S32-S34
    CrossrefPubMedGoogle Scholar
  • 31 Bereczky B, Gilly R, Raso E, Vago A, Timar J, Tovari J. Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest.  Clin Exp Metastasis. 2005;  22 69-76
    PubMedGoogle Scholar
  • 32 Kawase M, Sakagami H, Motohashi N et al.. Coumarin derivatives with tumor-specific cytotoxicity and multidrug resistance reversal activity.  In Vivo. 2005;  19 705-711
    PubMedGoogle Scholar
  • 33 Elinos-Baez C M, Leon F, Santos E. Effects of coumarin and 7OH-coumarin on bcl-2 and Bax expression in two human lung cancer cell lines in vitro.  Cell Biol Int. 2005;  29 703-708
    CrossrefPubMedGoogle Scholar
  • 34 Okamoto T, Kobayashi T, Yoshida S. Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas.  Curr Med Chem Anti-Canc Agents. 2005;  5 47-51
    PubMedGoogle Scholar
  • 35 Yim D, Singh R P, Agarwal C, Lee S, Chi H, Agarwal R. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells.  Cancer Res. 2005;  65 1035-1044
    PubMedGoogle Scholar
  • 36 Boccaccio C, Sabatino G, Medico E et al.. The MET oncogene drives a genetic programme linking cancer to hemostasis.  Nature. 2005;  434 396-400
    CrossrefPubMedGoogle Scholar
  • 37 Stenina O I, Plow E F. MET orchestrates cancer and blood coagulation.  Nat Med. 2005;  11 376-377
    PubMedGoogle Scholar
  • 38 Blom J W, Doggen C J, Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis.  JAMA. 2005;  293 715-722
    CrossrefPubMedGoogle Scholar
  • 39 Rickles F R, Levine M, Edwards R L. Hemostatic alterations in cancer patients.  Cancer Metastasis Rev. 1992;  11 237-248
    CrossrefPubMedGoogle Scholar
  • 40 Yonezawa S, Maruyama I, Sakae K, Igata A, Majerus P W, Sato E. Thrombomodulin as a marker for vascular tumors. Comparative study with factor VIII and Ulex europaeus I lectin.  Am J Clin Pathol. 1987;  88 405-411
    PubMedGoogle Scholar
  • 41 Appleton M A, Attanoos R L, Jasani B. Thrombomodulin as a marker of vascular and lymphatic tumours.  Histopathology. 1996;  29 153-157
    CrossrefPubMedGoogle Scholar
  • 42 Kim S J, Shiba E, Ishii H et al.. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study.  Anticancer Res. 1997;  17 2319-2323
    PubMedGoogle Scholar
  • 43 Jackson D E, Mitchell C A, Bird P, Salem H H, Hayman J A. Immunohistochemical localization of thrombomodulin in normal human skin and skin tumours.  J Pathol. 1995;  175 421-432
    PubMedGoogle Scholar
  • 44 Takebayashi Y, Yamada K, Maruyama I, Fujii R, Akiyama S, Aikou T. The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas.  Cancer Lett. 1995;  92 1-7
    CrossrefPubMedGoogle Scholar
  • 45 Yonezawa S, Maruyama I, Tanaka S, Nakamura T, Sato E. Immunohistochemical localization of thrombomodulin in chorionic diseases of the uterus and choriocarcinoma of the stomach. A comparative study with the distribution of human chorionic gonadotropin.  Cancer. 1988;  62 569-576
    CrossrefPubMedGoogle Scholar
  • 46 Tabata M, Yonezawa S, Sugihara K, Yamashita S, Maruyama I. The use of thrombomodulin to study epithelial cell differentiation in neoplastic and non-neoplastic oral lesions.  J Oral Pathol Med. 1995;  24 443-449
    CrossrefPubMedGoogle Scholar
  • 47 Ogawa H, Yonezawa S, Maruyama I et al.. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients.  Cancer Lett. 2000;  149 95-103
    CrossrefPubMedGoogle Scholar
  • 48 Tabata M, Sugihara K, Yonezawa S, Yamashita S, Maruyama I. An immunohistochemical study of thrombomodulin in oral squamous cell carcinoma and its association with invasive and metastatic potential.  J Oral Pathol Med. 1997;  26 258-264
    CrossrefPubMedGoogle Scholar
  • 49 Matsushita Y, Yoshiie K, Imamura Y et al.. A subcloned human esophageal squamous cell carcinoma cell line with low thrombomodulin expression showed increased invasiveness compared with a high thrombomodulin-expressing clone-thrombomodulin as a possible candidate for an adhesion molecule of squamous cell carcinoma.  Cancer Lett. 1998;  127 195-201
    CrossrefPubMedGoogle Scholar
  • 50 Hanly A M, Redmond M, Winter D C et al.. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival.  Br J Cancer. 2006;  94 1320-1325
    CrossrefPubMedGoogle Scholar
  • 51 Lindahl A K, Boffa M C, Abildgaard U. Increased plasma thrombomodulin in cancer patients.  Thromb Haemost. 1993;  69 112-114
    PubMedGoogle Scholar
  • 52 Boffa M C, Lapeyrere C, Berard M et al.. Plasma thrombomodulin level in malignancy varies according to the tumor type.  Nouv Rev Fr Hematol. 1994;  36(Suppl 1) S87-S88
    PubMedGoogle Scholar
  • 53 Raife T J, Lager D J, Madison K C et al.. Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation.  J Clin Invest. 1994;  93 1846-1851
    PubMedGoogle Scholar
  • 54 Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma.  Hepatology. 1995;  21 1285-1290
    PubMedGoogle Scholar
  • 55 Tezuka Y, Yonezawa S, Maruyama I et al.. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis.  Cancer Res. 1995;  55 4196-4200
    PubMedGoogle Scholar
  • 56 Huang H C, Shi G Y, Jiang S J et al.. Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain.  J Biol Chem. 2003;  278 46750-46759
    CrossrefPubMedGoogle Scholar
  • 57 Markuljak I, Ivankova J, Kubisz P. Thrombomodulin and von Willebrand factor in smokers and during smoking.  Nouv Rev Fr Hematol. 1995;  37 137-139
    PubMedGoogle Scholar
  • 58 Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer.  J Clin Invest. 2002;  109 987-991
    CrossrefPubMedGoogle Scholar
  • 59 Imada S, Yamaguchi H, Imada M. Differential expression of fetomodulin and tissue plasminogen activator to characterize parietal endoderm differentiation of F9 embryonal carcinoma cells.  Dev Biol. 1990;  141 426-430
    CrossrefPubMedGoogle Scholar
  • 60 Zhang Y, Weiler-Guettler H, Chen J et al.. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity.  J Clin Invest. 1998;  101 1301-1309
    PubMedGoogle Scholar
  • 61 Yamaguchi Y, Hisama N, Okajima K et al.. Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver.  Hepatology. 1997;  25 1136-1140
    CrossrefPubMedGoogle Scholar
  • 62 Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation.  Am J Physiol. 1996;  271(3 Pt 1) L470-L475
    PubMedGoogle Scholar
  • 63 Calnek D S, Grinnell B W. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor.  Exp Cell Res. 1998;  238 294-298
    CrossrefPubMedGoogle Scholar
  • 64 Seigneur M, Dufourcq P, Belloc F, Lenoble M, Renard M, Boisseau M R. Influence of pentoxifylline on membrane thrombomodulin levels in endothelial cells submitted to hypoxic conditions.  J Cardiovasc Pharmacol. 1995;  25(Suppl 2) S85-S87
    PubMedGoogle Scholar
  • 65 Ohdama S, Takano S, Ohashi K, Miyake S, Aoki N. Pentoxifylline prevents tumor necrosis factor-induced suppression of endothelial cell surface thrombomodulin.  Thromb Res. 1991;  62 745-755
    CrossrefPubMedGoogle Scholar
  • 66 Shi J, Wang J, Zheng H et al.. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation.  Blood Coagul Fibrinolysis. 2003;  14 575-585
    CrossrefPubMedGoogle Scholar
  • 67 Reny J L, Remones V, Fontana P et al.. The thrombomodulin-1208/-1209delTT gene promoter polymorphism does not affect basal or LPS-dependent monocyte TM mRNA transcription in healthy volunteers.  Thromb Haemost. 2005;  94 686-687
    PubMedGoogle Scholar
  • 68 Archipoff G, Beretz A, Freyssinet J M, Klein-Soyer C, Brisson C, Cazenave J P. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester.  Biochem J. 1991;  273 679-684
    PubMedGoogle Scholar

Ann M HanlyM.D. 

c/o Desmond C. Winter, M.D., Consultant General and Colorectal Surgeon

St. Vincents University Hospital, Dublin 4, Ireland

Email: amhanly@indigo.ie